125,226 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Cerity Partners LLC

Cerity Partners LLC bought a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 125,226 shares of the company’s stock, valued at approximately $1,878,000. Cerity Partners LLC owned approximately 0.53% of UroGen Pharma as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of URGN. Rice Hall James & Associates LLC increased its stake in UroGen Pharma by 6.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 107,990 shares of the company’s stock worth $941,000 after purchasing an additional 6,631 shares in the last quarter. Swiss National Bank boosted its position in UroGen Pharma by 9.1% during the 1st quarter. Swiss National Bank now owns 47,900 shares of the company’s stock worth $417,000 after acquiring an additional 4,000 shares during the last quarter. JPMorgan Chase & Co. boosted its position in UroGen Pharma by 30.8% during the 1st quarter. JPMorgan Chase & Co. now owns 81,867 shares of the company’s stock worth $714,000 after acquiring an additional 19,280 shares during the last quarter. Bank of New York Mellon Corp boosted its position in UroGen Pharma by 11.9% during the 1st quarter. Bank of New York Mellon Corp now owns 67,486 shares of the company’s stock worth $588,000 after acquiring an additional 7,197 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in UroGen Pharma during the 1st quarter worth approximately $215,000. 91.29% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Mark Schoenberg sold 12,000 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $14.05, for a total value of $168,600.00. Following the completion of the sale, the insider now owns 139,437 shares of the company’s stock, valued at approximately $1,959,089.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other UroGen Pharma news, General Counsel Jason Drew Smith sold 4,993 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total transaction of $78,589.82. Following the completion of the sale, the general counsel now owns 18,824 shares of the company’s stock, valued at approximately $296,289.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 12,000 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a total value of $168,600.00. Following the sale, the insider now directly owns 139,437 shares of the company’s stock, valued at approximately $1,959,089.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,782 shares of company stock valued at $306,829. 11.13% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Oppenheimer reduced their price target on UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a research report on Friday, March 15th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 price target on shares of UroGen Pharma in a research report on Thursday.

UroGen Pharma Trading Down 3.7 %

NASDAQ URGN opened at $13.73 on Friday. The company has a market cap of $321.97 million, a PE ratio of -3.68 and a beta of 1.07. UroGen Pharma Ltd. has a 12 month low of $8.69 and a 12 month high of $24.13. The stock has a 50 day moving average of $16.19 and a 200-day moving average of $14.59.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The firm had revenue of $23.53 million during the quarter, compared to the consensus estimate of $22.30 million. As a group, sell-side analysts predict that UroGen Pharma Ltd. will post -3.59 EPS for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.